Document:

<PAGE>

                                                                    EXHIBIT 10.1

                         CHINA WORLD TRADE CORPORATION
                         -----------------------------
                            2000 STOCK OPTION PLAN
                            ----------------------

     1.   Establishment, Purpose and Definitions.
          --------------------------------------

          (a) The 2000 Stock Option Plan (the "Plan") of China World Trade
Corporation, a Nevada corporation (the "Company"), is hereby adopted.  The Plan
shall provide for the issuance of incentive stock options ("ISOs") and
nonqualified stock options ("NSOs") to purchase the Stock of the Company.

          (b) The purpose of this Plan is to promote the long-term success of
the Company by attracting, motivating and retaining directors, officers and key
employees and consultants of the Company and its Affiliates (the "Participants")
through the use of competitive long-term incentives which are tied to
shareholder value.  The Plan seeks to balance Participants' and shareholder
interests by providing incentives to the Participants in the form of stock
options which offer rewards for achieving the long-term strategic and financial
objectives of the Company.

          (c) The Plan is intended to provide a means whereby Participants may
be given an opportunity to purchase shares of Stock of the Company pursuant to
(i) options which may qualify as ISOs under Section 422 of the Internal Revenue
Code of 1986, as amended (the "Internal Revenue Code"), or (ii) NSOs which may
not so qualify.

          (d) The term "Affiliates" as used in this Plan means, in the case of
an ISO, parent or subsidiary corporations, as defined in Section 424(e) and (f)
of the Code (but substituting "the Company" for "employer corporation"),
including parents or subsidiaries which become such after adoption of the Plan,
and in all other cases, any entity which is controlled by or which controls the
Company.

     2.   Administration of the Plan.
          --------------------------

          (a) The Plan shall be administered by the Board of Directors (the
"Board") or such other committee appointed by the Board to administer the Plan
(the "Committee") or in the absence of a Committee, by the Board acting in such
capacity, in which case reference herein to the Committee shall mean the Board.

          (b) The Committee may from time to time determine which Participants
(each an "option holder") shall be granted options under the Plan, the terms
thereof (including without limitation determining whether the option is an ISO
and the times at which the options shall become exercisable), and the number of
shares of Common Stock for which an option or options may be granted.

          (c) If rights of the Company to repurchase Stock are imposed, the
Board or the Committee may, in its sole discretion, accelerate, in whole or in
part, the time for lapsing of any rights of the Company to repurchase shares of
such Stock or forfeiture restrictions.
<PAGE>

          (d) If rights of the Company to repurchase Stock are imposed, the
certificates evidencing such shares of Stock awarded hereunder, although issued
in the name of the option holder concerned, shall be held by the Company or a
third party designated by the Committee in escrow subject to delivery to the
option holder or to the Company at such times and in such amounts as shall be
directed by the Board under the terms of this Plan.  Share certificates
representing Stock which is subject to repurchase rights shall have imprinted or
typed thereon a legend or legends summarizing or referring to the repurchase
rights.

          (e) The Board or the Committee shall have the sole authority, in its
absolute discretion, to adopt, amend and rescind such rules and regulations,
consistent with the provisions of the Plan, as, in its opinion, may be advisable
in the administration of the Plan, to construe and interpret the Plan, the rules
and regulations, and the instruments evidencing options granted under the Plan
and to make all other determinations deemed necessary or advisable for the
administration of the Plan.  All decisions, determinations and interpretations
of the Committee shall be binding on all option holders under the Plan.

     3.   Stock Subject to the Plan.
          -------------------------

          (a) "Stock" shall mean the Common Stock of the Company or such stock
as may be changed as contemplated by Section 3(c) below.  Stock shall include
shares drawn from either the Company's authorized but unissued shares of Common
Stock or from reacquired shares of Common Stock, including without limitation
shares repurchased by the Company in the open market.

          (b) Options may be granted under the Plan from time to time to
eligible persons to purchase an aggregate of up to 3,000,000 shares of Stock.
Stock options awarded pursuant to the Plan which are forfeited, terminated,
surrendered or cancelled for any reason prior to exercise shall again become
available for grants under the Plan (including any option cancelled in
accordance with the cancellation regrant provisions of Section 6(f) herein).

          (c) If there shall be any change in the Stock subject to the Plan,
including Stock subject to any option granted hereunder, through merger,
consolidation, recapitalization, reorganization, reincorporation, stock split,
reverse stock split, stock dividend, combination or reclassification of the
Company's Stock or other similar events, an appropriate adjustment shall be made
by the Committee in the number of shares and/or the option price with respect to
any unexercised shares of Stock.  Consistent with the foregoing, in the event
that the outstanding Stock is changed into another class or series of capital
stock of the Company, outstanding options to purchase Stock granted under the
Plan shall become options to purchase such other class or series and the
provisions of this Section 3(c) shall apply to such new class or series.

          (d) The Company may grant options under the Plan in substitution for
options held by employees of another company who become employees of the Company
as a result of merger or consolidation.  The Company may direct that substitute
options be granted on such terms and conditions as deemed appropriate by the
Board or the Committee.

                                       2
<PAGE>

          (e) The aggregate number of shares of Stock approved by the Plan may
not be exceeded without amending the Plan and obtaining shareholder approval
within twelve months of such amendment.

     4.   Eligibility.
          -----------

          Persons who shall be eligible to receive stock options granted under
the Plan shall be those Participants referred to in Section 1(b) above;
provided, however, that (i) ISOs may only be granted to employees of the Company
and its Affiliates and (ii) any person holding capital stock possessing more
than 10% of the total combined voting power of all classes of capital stock of
the Company or any Affiliate shall not be eligible to receive ISOs unless the
exercise price per share of Stock is at least 110% of the fair market value of
the Stock on the date the option is granted.

     5.   Exercise Price for Options Granted under the Plan.
          -------------------------------------------------

          (a) All ISOs will have option exercise prices per option share equal
to the fair market value of a share of the Stock on the date the option is
granted, except that in the case of any option granted to any person possessing
more than 10% of the total combined voting power of all classes of stock of the
Company or any Affiliate (a "Ten Percent Stockholder") the price shall be not
less than 110% of such fair market value.  The option exercise prices per option
for NSO's shall be as determined by the Committee, provided that NSO's shall
have an exercise price that is not less than 85% of such fair market value
except that the exercise price shall be 110% of such fair market value in the
case of NSO's granted to any Ten Percent Stockholder.  The price of ISOs or NSOs
granted under the Plan shall be subject to adjustment to the extent provided in
Section 3(c) above.

          (b) The fair market value on the date of grant shall be determined
based upon the closing price on an exchange on that day or, if the Stock is not
listed on an exchange, on the average of the closing bid and asked prices in the
Over the Counter Market on that day.

     6.   Terms and Conditions of Options.
          -------------------------------

          (a) Each option granted pursuant to the Plan shall be evidenced by a
written stock option agreement (the "Option Agreement") executed by the Company
and the person to whom such option is granted.  The Option Agreement shall
designate whether the option is an ISO or an NSO.

          (b) The term of each ISO and NSO shall be no more than 10 years,
except that the term of each ISO issued to any person possessing more than 10%
of the voting power of all classes of stock of the Company or any Affiliate
shall be no more than 5 years.

          (c) In the case of ISOs, the aggregate fair market value (determined
as of the time such option is granted) of the Stock to which ISOs are
exercisable for the first time by any individual during any calendar year (under
this Plan and any other plans of the Company or its Affiliates if any) shall not
exceed the amount specified in Section 422(d) of the Internal Revenue Code, or
any successor provision in effect at the time an ISO becomes exercisable.

                                       3
<PAGE>

          (d) The Option Agreement may contain such other terms, provisions and
conditions regarding vesting, repurchase or other similar provisions as may be
determined by the Committee and not inconsistent with this Plan.  If an option,
or any part thereof, is intended to qualify as an ISO, the Option Agreement
shall contain those terms and conditions which the Committee determine are
necessary to so qualify under Section 422 of the Internal Revenue Code.

          (e) The Committee shall have full power and authority to extend the
period of time for which any option granted under the Plan is to remain
exercisable following the option holder's cessation of service as an employee or
consultant, including without limitation cessation as a result of death or
disability; provided, however, that in no event shall such option be exercisable
after the specified expiration date of the option term.

          (f) The Committee shall have full power and authority to effect at any
time and from time to time, with the consent of the affected option holders, the
cancellation of any or all outstanding options under the Plan and to grant in
substitution new options under the Plan covering the same or different numbers
of shares of Stock with the same or different exercise prices.

          (g) As a condition to option grants under the Plan, the option holder
agrees to grant the Company the repurchase rights as Company may at its option
require and as may be set forth in the Option Agreement or a separate repurchase
agreement.

          (h) Any option granted under the Plan may be subject to a vesting
schedule as provided in the Option Agreement and, except as provided in this
Section 6 herein, only the vested portion of such option may be exercised at any
time during the Option Period.  Options shall become exercisable at the rate of
at least 20% per year over five years from the date the option is granted,
subject to reasonable conditions such as continued employment. However, in the
case of an option granted to officers, directors or consultants of the Company
or any of its Affiliates, the option may become fully exercisable, subject to
reasonable conditions such as continued employment, at any time or during any
period established by the Company or any of its Affiliates.  All rights to
exercise any option shall lapse and be of no further effect whatsoever
immediately if the option holder's service as an employee is terminated for
"Cause" (as hereinafter defined).  The unvested portion of the option will lapse
and be of no further effect immediately upon any termination of employment of
the option holder for any reason. Unless employment is terminated for Cause, the
right to exercise an option in the event of termination of employment, to the
extent that the Participant is otherwise entitled to exercise an option on the
date employment terminates, shall be:

              (i)   at least six months from the date of termination of
employment if termination was caused by death or disability;

              (ii)  at least 90 days from the date of termination if termination
of employment was caused by other than death or disability; and

              (iii) but in no event later than the remaining term of the option.

                                       4
<PAGE>

          There shall be "Cause" for termination as set forth in any applicable
employment or consulting agreement or, in the absence of such agreement if (i)
the option holder is convicted of a felony, (ii) the option holder engages in
any fraudulent or other dishonest act to the detriment of the Company, (iii) the
option holder fails to report for work on a regular basis, except for periods of
authorized absence or bona fide illness, (iv) the option holder misappropriates
trade secrets, customer lists or other proprietary information belonging to the
Company for the option holder's own benefit or for the benefit of a competitor,
(v) the option holder engages in any willful misconduct designed to harm the
Company or its shareholders, or (vi) the option holder fails to perform properly
assigned duties with a failure to cure after 20 days notice.

          (i) No fractional shares of Stock shall be issued under the Plan,
whether by initial grants or any adjustments to the Plan.

     7.   Use of Proceeds.
          ---------------

          Cash proceeds realized from the sale of Stock under the Plan shall
constitute general funds of the Company.

     8.   Amendment, Suspension or Termination of the Plan.
          ------------------------------------------------

          (a) The Board may at any time suspend or terminate the Plan, and may
amend it from time to time in such respects as the Board may deem advisable
provided that (i) such amendment, suspension or termination complies with all
applicable state and federal requirements and requirements of any stock exchange
on which the Stock is then listed, including any applicable requirement that the
Plan or an amendment to the Plan be approved by the shareholders.  The Plan
shall terminate on the earlier of (i) ten (10) years from April 6, 2000, (ii)
the date on which no additional shares of Stock are available for issuance under
the Plan, or (iii) ten years after the date the Plan is approved by the
Company's stockholders.

          (b) No option may be granted during any suspension or after the
termination of the Plan, and no amendment, suspension or termination of the Plan
shall, without the option holder's consent, alter or impair any rights or
obligations under any option granted under the Plan.

          (c) The Committee, with the consent of affected option holders, shall
have the authority to cancel any or all outstanding options under the Plan and
grant new options having an exercise price which may be higher or lower than the
exercise price of cancelled options.

     9.   Assignability of Options and Rights.
          -----------------------------------

          (a) Subject to Subparagraph (b), no Option issued under the Plan shall
be assignable or transferable by an option holder other than by will or the laws
of descent and distribution.  An Option awarded to an option holder during such
option holder's lifetime shall be exercisable only by an option holder or his or
her guardian or legal representation.

          (b) Notwithstanding Subparagraph (a), in the case of an NSO, an option
holder shall be permitted to transfer the Option to the option holder's spouse,
adult lineal

                                       5
<PAGE>

descendants, adult spouses of adult lineal descendants and trusts for the
benefit of the option holder's minor or adult lineal descendants (a "Related
Transferee") if the Option Agreement under which the Option is granted so
specifies. If the Option is transferred to a Related Transferee pursuant to the
preceding sentence, the Related Transferee shall, upon exercise of the Option,
hold the Stock subject to all the provisions of the transferor's Option
Agreement in the same manner as the transferor and shall execute and deliver to
the Company such instruments as the Company shall require to evidence the same.

     10.  Payment Upon Exercise.
          ---------------------

          Payment of the purchase price upon exercise of any option or right to
purchase Stock granted under this Plan shall be made by giving the Company
written notice of such exercise, specifying the number of such shares of Stock
as to which the option is exercised.  Such notice shall be accompanied by
payment of an amount equal to the Option Price of such shares of Stock.  Such
payment may be (i) cash, (ii) by check drawn against sufficient funds, (iii) at
the discretion of the Committee, by delivery to the Company of the option
holder's promissory note, (iv) such other consideration as the Committee, in its
sole discretion, determines and is consistent with the Plan's purpose and
applicable law, or (v) any combination of the foregoing.  Any Stock used to
exercise options to purchase Stock (including Stock withheld upon the exercise
of an option to pay the purchase price of the shares of Stock as to which the
option is exercised) shall be valued in accordance with procedures established
by the Committee.  Any promissory note used to exercise options to purchase
Stock shall be a full recourse, interest-bearing obligation secured by Stock in
the Company being purchased and containing such terms as the Committee shall
determine.  If a promissory note is used to exercise options the option holder
agrees to execute such further documents as the Company may deem necessary or
appropriate in connection with issuing the promissory note, perfecting a
security interest in the stock purchased with the promissory note and any
related terms the Company may propose.  Such further documents may include,
without limitation, a security agreement and an assignment separate from
certificate.  If accepted by the Committee in its discretion, such consideration
also may be paid through a broker-dealer sale and remittance procedure pursuant
to which the option holder (I) shall provide irrevocable written instructions to
a designated brokerage firm to effect the immediate sale of the purchased Stock
and remit to the Company, out of the sale proceeds available on the settlement
date, sufficient funds to cover the aggregate option price payable for the
purchased Stock plus all applicable Federal and State income and employment
taxes required to be withheld by the Company in connection with such purchase
and (II) shall provide written directives to the Company to deliver the
certificates for the purchased Stock directly to such brokerage firm in order to
complete the sale transaction.

     11.  Withholding Taxes.
          -----------------

          (a) Shares of Stock issued hereunder shall be delivered to an option
holder only upon payment by such person to the Company of the amount of any
withholding tax required by applicable federal, state, local or foreign law.
The Company shall not be required to issue any Stock to an option holder until
such obligations are satisfied.

          (b) The Committee may, under such terms and conditions as it deems
appropriate, authorize an option holder to satisfy withholding tax obligations
under this Section

                                       6
<PAGE>

11 by surrendering a portion of any Stock previously issued to the option holder
or by electing to have the Company withhold shares of Stock from the Stock to be
issued to the option holder, in each case having a fair market value equal to
the amount of the withholding tax required to be withheld.

     12.  Corporate Transactions.
          ----------------------

          (a) For the purpose of this Section 12, a "Corporate Transaction"
shall include any of the following shareholder-approved transactions to which
the Company is a party:

              (i)  a merger or consolidation in which the Company is not the
surviving entity, except for a transaction the principal purpose of which is to
change the State of the Company's incorporation; or

              (ii) the sale, transfer or other disposition of all or
substantially all of the assets of the Company in liquidation or dissolution of
the Company.

          (b) Upon the occurrence of a Corporate Transaction, if the surviving
corporation or the purchaser, as the case may be, does not assume the
obligations of the Company under the Plan, then irrespective of the vesting
provisions contained in individual option agreements, all outstanding options
shall become immediately exercisable in full and each option holder will be
afforded an opportunity to exercise their options prior to the consummation of
the merger or sale transaction so that they can participate on a pro rata basis
in the transaction based upon the number of shares of Stock purchased by them on
exercise of options if they so desire.  To the extent that the Plan is
unaffected and assumed by the successor corporation or its parent company a
Corporate Transaction will have no effect on outstanding options and the options
shall continue in effect according to their terms.

          (c) Each outstanding option under this Plan which is assumed in
connection with the Corporate Transaction or is otherwise to continue in effect
shall be appropriately adjusted, immediately after such Corporate Transaction,
to apply and pertain to the number and class of securities which would have been
issued to the option holder in connection with the consummation of such
Corporate Transaction had such person exercised the option immediately prior to
such Corporate Transaction.  Appropriate adjustments shall also be made to the
option price payable per share, provided the aggregate option price payable for
such securities shall remain the same.  In addition, the class and number of
securities available for issuance under this Plan following the consummation of
the Corporate Transaction shall be appropriately adjusted.

          (d) The grant of options under this Plan shall in no way affect the
right of the Company to adjust, reclassify, reorganize or otherwise change its
capital or business structure or to merge, consolidate, dissolve, liquidate or
sell or transfer all or any part of its business or assets.

     13.  Loans or Guarantee of Loans.
          ---------------------------

          (a) The Committee may, in its discretion, assist any option holder in
the exercise of options granted under this Plan, including the satisfaction of
any income and employment tax obligations arising therefrom by (i) authorizing
the extension of a loan from the

                                       7
<PAGE>

Company to such option holder, (ii) permitting the option holder to pay the
exercise price for the Stock in installments over a period of years or (iii)
authorizing a guarantee by the Company of a third party loan to the option
holder. The terms of any loan, installment method of payment or guarantee
(including the interest rate and terms of repayment) will be upon such terms as
the Committee specifies in the applicable option or issuance agreement or
otherwise deems appropriate under the circumstances. Loans, installment payments
and guarantees may be granted with or without security or collateral (other than
to option holders who are not employees, in which event the loan must be
adequately secured by collateral other than the purchased Stock). However, the
maximum credit available to the option holder may not exceed the exercise or
purchase price of the acquired shares of Stock plus any Federal and State income
and employment tax liability incurred by the option holder in connection with
the acquisition of such shares of Stock.

          (b) The Committee may, in its absolute discretion, determine that one
or more loans extended under this financial assistance program shall be subject
to forgiveness by the Company in whole or in part upon such terms and conditions
as the Committee may deem appropriate.

     14.  Regulatory Approvals.
          --------------------

          The obligation of the Company with respect to Stock issued under the
Plan shall be subject to all applicable laws, rules and regulations and such
approvals by any governmental agencies or stock exchanges as may be required.
The Company reserves the right to restrict, in whole or in part, the delivery of
Stock under the Plan until such time as any legal requirements or regulations
have been met relating to the issuance of Stock, to their registration or
qualification under the Securities Exchange Act of 1934, if applicable, or any
applicable state securities laws, or to their listing on any stock exchange at
which time such listing may be applicable.

     15.  No Employment/Service Rights.
          ----------------------------

          Neither the action of the Company in establishing this Plan, nor any
action taken by the Board or the Committee hereunder, nor any provision of this
Plan shall be construed so as to grant any individual the right to remain in the
employ or service of the Company (or any parent, subsidiary or affiliated
corporation) for any period of specific duration, and the Company (or any
parent, subsidiary or affiliated corporation retaining the services of such
individual) may terminate or change the terms of such individual's employment or
service at any time and for any reason, with or without cause.

     16.  Miscellaneous Provisions.
          ------------------------

          (a) The provisions of this Plan shall be governed by the laws of the
State of California, as such laws are applied to contracts entered into and
performed in such State, without regard to its rules concerning conflicts of
law.

          (b) The provisions of this Plan shall inure to the benefit of, and be
binding upon, the Company and its successors or assigns, whether by Corporate
Transaction or otherwise, and the option holders, the legal representatives of
their respective estates, their respective heirs or legatees and their permitted
assignees.

                                       8
<PAGE>

          (c) The option holders shall have no dividend rights, voting rights or
any other rights as a shareholder with respect to any options under the Plan
prior to the issuance of a stock certificate for such Stock.

          (d) With respect to grants to non-U.S. residents, options may be
granted hereunder which may vary from the terms of the Plan but which are
consistent with the terms hereof to the extent necessary or appropriate to
comply with foreign laws including but not limited to tax laws.

          (e) Any option exercised before shareholder approval is obtained shall
be rescinded if stockholder approval is not obtained within 12 months before or
after the Plan. Such shares shall not be counted in determining whether such
approval is obtained.

          (f) The Company shall provide annual financial statements of the
Company to each Participant holding an outstanding option under the Plan.

                                       9<PAGE>

                                                                   Exhibit 10.18

                      [CONFIDENTIAL TREATMENT REQUESTED.
           CERTAIN PORTIONS OF THIS AGREEMENT HAVE BEEN REDACTED
             AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION.]

                       COLLABORATIVE RESEARCH AGREEMENT
                       --------------------------------

     This COLLABORATIVE RESEARCH AGREEMENT ("Agreement") is entered into as of
December 28, 2000 by and between PFIZER INC, a Delaware corporation, having an
office at 235 East 42nd Street, New York, New York 10017 and its Affiliates
("Pfizer"), and XENOGEN BIOSCIENCES ("Xenogen Cranbury"), an Ohio Corporation,
with an office at 5 Cedar Brook Drive, Cranbury, NJ 08512, and a wholly owned
subsidiary of Xenogen Corp. ("Xenogen").

                                   RECITALS
                                   --------

     WHEREAS, Pfizer wishes to develop Assays (as defined below) to use in
performing phenotypic analysis of Transgenic Animals (as defined below) with a
view toward identifying the role of interesting genes in human disease processes
and toward validating gene function in research animals; and

     WHEREAS, Pfizer has detailed protocols for individual Assays;

     WHEREAS, Xenogen Cranbury has expertise in developing and conducting such
Assays and in performing phenotypic analysis of Transgenic Animals using such
Assays; and

     WHEREAS, Xenogen Cranbury desires to collaborate with Pfizer on the
development of such Assay packages for Transgenic Animals;

     NOW, THEREFORE, in consideration of the promises and mutual covenants
contained herein, Xenogen Cranbury and Pfizer agree as follows:

1.   DEFINITIONS.
     -----------
          Whenever used in this Agreement, the terms defined in this Section 1
shall have the meanings specified.
<PAGE>

                                       2

     1.1  "Affiliate" means, with respect to Pfizer, any legal entity
           ---------
controlling, controlled by, or under common control with Pfizer; and with
respect to Xenogen Cranbury, any legal entity controlling, controlled by, or
under common control with Xenogen Cranbury; where, in all cases, "control" means
the ownership, directly or indirectly, of fifty percent (50%) or more of the
voting capital shares or similar voting securities of the other entity.

     1.2  "Area" means: (a) research to develop a battery of phenotypic and
           ----
challenge Assays on Transgenic Animals; (b) performing phenotypic analysis on
Transgenic Animals using such Assays; and (c) any other activities identified in
the course of the research or development hereunder; in all cases only as
specified in the Research Plan (as defined below).

     1.3  "Assay" means any of the Level I Assays, the Level II Assays, the
           -----
Level IIIP Assays, or the Level IIIXC Assays as defined below.

     1.4  "Contract Period" means the period beginning on the Effective Date and
           ---------------
ending on the date on which this Agreement terminates.

     1.5  "Contract Research Service" means a research service performed for a
           -------------------------
Third Party (as defined below) for a fee or other consideration.

     1.6  "Control Animal" means any mouse, other than a Transgenic Animal (as
           --------------
defined below), acquired by Xenogen Cranbury under this Agreement, including,
but not limited to: ***

     1.7  "Effective Date" means December 28, 2000.
           --------------

     1.8  "Level I Assay" means any assay identified as a Level I Assay in
           -------------
Exhibit B, as annexed hereto, or as the parties may from time to time identify
as a Level I Assay in a written amendment to the Research Plan.

     1.9  "Level II Assay" means any assay identified as a Level II Assay in
            --------------
Exhibit B, as annexed hereto, or as the parties may from time to time identify
as a Level II Assay in a written amendment to the Research Plan.

     1.10 "Level III Assay" means a Level IIIP Assay or a Level IIIXC Assay
           ---------------
(which may be collectively referred to as Level III Assays).

          1.10.1  "Level IIIP Assay" means any assay incorporating Pfizer
                   ----------------
Technology and Pfizer Confidential Information (both as defined below)
identified as a Level IIIP Assay in Exhibit B, as annexed hereto, or as the
parties may from time to time identify as a Level IIIP Assay in a written
amendment to the Research Plan.

_______________________
*** CONFIDENTIAL TREATMENT REQUESTED
<PAGE>

                                       3

          1.10.2  "Level IIIXC Assay" means any assay incorporating Xenogen
                   -----------------
Cranbury Technology and Xenogen Cranbury Confidential Information (both as
defined below) identified as a Level IIIXC Assay in Exhibit B, as annexed
hereto, or as the parties may from time to time identify as a Level IIIXC Assay
in a written amendment to the Research Plan.  The designation of the Level IIIXC
Assay shall be at the sole discretion of Xenogen Cranbury and Level IIIXC Assay
will not be part of Program Technology.

     1.11 "Period of Exclusivity" means, with respect to any Level III Assay,
           ---------------------
the period ending on the second anniversary of the termination or expiration of
this Agreement.

     1.12 "Pfizer Compound" means any Pfizer compound, any library of Pfizer
           ---------------
compounds, and intermediates of any Pfizer compound, any impurities of any
Pfizer compound, and any information regarding the chemical or biochemical
properties of any Pfizer compound that Pfizer delivers to Xenogen Cranbury under
this Agreement.

     1.13 "Pfizer Confidential Information" means (a) all Results (as defined in
           -------------------------------
Section 1.19) and Program Technology, and (b) all other information about any
element of Pfizer Technology, including, without limitation, protocols, which
Pfizer discloses to Xenogen Cranbury and designates as "Confidential," where
such disclosure is either in writing or within 30 days of such disclosure Pfizer
provides Xenogen Cranbury a memorandum identifying the disclosure and
characterizing it as confidential.  Notwithstanding the foregoing, "Pfizer
Confidential Information" shall not include any information that (i) at the time
of disclosure to Xenogen Cranbury, is already known by Xenogen Cranbury other
than by virtue of a prior confidential disclosure to Xenogen Cranbury by Pfizer;
or (ii) is or becomes disclosed in published literature, or otherwise is or
becomes generally known to the public, in each case through no fault or omission
of Xenogen Cranbury; or (iii) is obtained by Xenogen Cranbury from a third party
free from any obligation of confidentiality to Pfizer.

     1.14 "Pfizer Technology" means (a) Technology developed prior to the
           -----------------
Effective Date by employees of, or consultants to, Pfizer acting alone or
jointly with third parties (but, in the case of consultants or third parties,
only to the extent Pfizer has the right to grant rights to such Technology), and
including without limitation any Transgenic Animals; (b) Program Technology; or
(c) Results.

     1.15 "Program Technology" means Technology developed, in the course of
           ------------------
performing the Research Program by employees of or consultants to Pfizer or
Xenogen Cranbury solely or jointly with each other, excluding Results and Level
<PAGE>

                                       4

IIIXC Assays, but including, without limitation, Level I, Level II and Level
IIIP Assays.

     1.16 "Research Plan" means the written plan describing the research and
           -------------
development in the Area to be carried out during the Contract Period by Pfizer
and Xenogen Cranbury pursuant to this Agreement. The Research Plan is attached
to and made a part of this Agreement as Exhibit A. The Research Plan may be
amended from time to time by agreement of the parties. Any such amended Research
Plan shall be appended hereto as an Exhibit.

     1.17 "Research Program" is the collaborative research program in the Area
           ----------------
conducted by Pfizer and Xenogen Cranbury pursuant to the Research Plan.

     1.18 "Results" means any data or information generated by either party in
           -------
the course of performing the Research Program, including, without limitation,
any data relating to the development and use of any Assay, and any data or
information resulting from the application of any Assay to any Transgenic Animal
or Control Animal.

     1.19 "Technology" means and includes all materials, technology, technical
           ----------
data and information, inventions, methods, know-how, expertise and trade secrets
within the Area.

     1.20 "Third Party" means any party other than Pfizer, Xenogen, or Xenogen
           -----------
Cranbury.

     1.21 "Transgenic Animal" means any genetically modified mouse supplied by
           -----------------
Pfizer to Xenogen Cranbury under this Agreement.

     1.22 "Xenogen Cranbury Technology" means Technology that is or was
           ---------------------------
developed by employees of, or consultants to, Xenogen Cranbury alone or jointly
with third parties prior to the Effective Date, but, in the case of consultants
or third parties, only to the extent Xenogen Cranbury has the right to grant
rights to such Technology, and specifically excluding, in all cases: (i) any
technology concerning or relating to in vivo imaging; and (ii) light-producing
cells, micro-organisms or animals; and (iii) other technologies intended for use
with (i) or (ii).

     1.23 "Xenogen Cranbury Confidential Information" means (a) all information
           -----------------------------------------
about any element of Xenogen Cranbury Technology which Xenogen Cranbury
discloses to Pfizer and designates as "Confidential," where such disclosure is
either in writing or within 30 days of such disclosure Xenogen Cranbury provides
Pfizer a memorandum identifying the disclosure and characterizing it as
confidential.  Notwithstanding the foregoing, "Xenogen Cranbury Confidential
Information" shall not include any information that (i) at the
<PAGE>

                                       5

time of disclosure to Pfizer, is already known by Pfizer other than by virtue of
a prior confidential disclosure to Pfizer by Xenogen Cranbury; or (ii) is or
becomes disclosed in published literature, or otherwise is or becomes generally
known to the public, in each case through no fault or omission of Pfizer; or
(iii) is obtained by Pfizer from a third party free from any obligation of
confidentiality to Xenogen Cranbury.

2.   COLLABORATIVE RESEARCH PROGRAM
     ------------------------------

     2.1  Purpose.  Xenogen Cranbury and Pfizer each shall conduct their
          -------
respective responsibilities of the Research Program throughout the Contract
Period.  The objective of the Research Program is to develop specific phenotypic
assays and to validate and test such assays on Transgenic Animals.

     2.2  Research Plan.  The initial Research Plan is described in the attached
          -------------
Exhibit A.  As the Research Plan is modified by mutual agreement of the parties,
the modified version shall be appended to Exhibit A and made part of this
Agreement.

     2.3  Research Committee
          ------------------

          2.3.1  Purpose.  Pfizer and Xenogen Cranbury shall establish a
                 -------
Research Committee (the "Research Committee"):

                 (a)  to review and evaluate progress under the Research Plan;

                 (b)  to prepare the Research Plan, and amendments and evaluate
                 the need for extensions to the Agreement;

                 (c)  to propose, discuss, select and document in writing, the
                 mutual acceptance of Assays in the Area to be included in the
                 Research Plan;

                 (d)  to coordinate and monitor publication as provided under
                 Section 4.7 of this Agreement, of Results (this function shall
                 survive termination of this Agreement for five (5) years); and

                 (e)  to designate Assays as either Level I, Level II, or Level
                 III.

          2.3.2  Membership.  Each of Pfizer and Xenogen Cranbury shall appoint,
                 ----------
in its sole discretion, three members to the Research Committee. Each party may
replace its respective Research Committee members at any time, with prior
written notice to the other party hereto.  The parties initially appoint the
following members:
<PAGE>

                                       6

     Pfizer Appointees:             ***

     Xenogen Cranbury Appointees:   ***

          2.3.3  Chair. The Research Committee shall be chaired by two co-
                 -----
chairpersons, one appointed by Pfizer and the other appointed by Xenogen
Cranbury.

          2.3.4  Meetings. The Research Committee shall meet at least quarterly,
                 --------
at places selected by each party in turn and on dates mutually agreed by the
parties. The location of the first meeting of the Research Committee shall be at
Pfizer's election. Representatives of Pfizer or Xenogen Cranbury or both, in
addition to members of the Research Committee, may attend such meetings at the
invitation of either party. Any materials to be submitted to the members of the
Research Committee shall be delivered to each member not less than five (5)
business days before the meeting.

          2.3.5  Minutes.  The Research Committee shall keep accurate minutes of
                 -------
its deliberations which record all proposed decisions and all actions
recommended or taken. Drafts of the minutes shall be delivered to all Research
Committee members within five (5) business days after each meeting. The party
choosing the location for the meeting shall be responsible for the preparation
and circulation of the draft minutes. Draft minutes shall be edited by the co-
chairpersons and shall be issued in final form only with their approval and
agreement.

          2.3.6  Decisions.  All decisions of the Research Committee shall be
                 ---------
made by mutual agreement except that Pfizer, in its sole discretion, shall
decide the overall direction of the Research Program.

          2.3.7  Expenses.   Pfizer and Xenogen Cranbury shall each bear all
                 --------
expenses, including reasonable travel, related to the participation of their
designated members of the Research Committee, respectively.

     2.4  Reports and Materials.
          ---------------------

          2.4.1  Reports.  During the Contract Period, Xenogen Cranbury shall
                 -------
furnish to the Research Committee:

          (a)    summary written reports within fifteen (15) days after the end
                 of each three-month period commencing on the
________________________
*** CONFIDENTIAL TREATMENT REQUESTED
<PAGE>

                                       7

                 Effective Date, describing the progress under the Research
                 Plan;

          (b)                 a comprehensive written report within thirty (30)
                 days after the end of the Contract Period, describing in detail
                 the work accomplished by it under the Research Plan during the
                 Contract Period and discussing and evaluating the results of
                 such work;

          (c)                 a written report describing the detailed protocols
                 of all assays developed under the Research Program;

          (d)                 a written report detailing Results. Such reports
                 will be submitted at the end of Phase 1A, 1B and Phase 2 of
                 Tracks I and II; and

          (e)                 any report containing information that Xenogen
                 Cranbury may generate using Level II Assays for Third Parties
                 during the Term, pursuant to Section 4.3.

          2.4.2 Materials.  During the Contract Period, each party shall provide
                ---------
the other, to the extent necessary for the receiving party to perform its
responsibilities under the Research Plan, with Transgenic Animals, Control
Animals, Pfizer Compounds, which are part of Pfizer Technology, Xenogen Cranbury
Technology or Program Technology.  Such supply of materials and Technology shall
be in accordance with the Research Plan, or as a party may otherwise reasonably
request from time to time and the other party agree to provide.  To the extent
that the quantities of materials requested and supplied by the parties exceed
the quantities required to be provided under the Research Plan, the requesting
party shall reimburse the other for the reasonable costs of such materials.
Each party shall use and store such materials in accordance with all applicable
laws and regulations, and shall exert due care in so doing.

     2.5  Laboratory Facilities and Personnel.  Xenogen Cranbury and Pfizer each
          -----------------------------------
shall provide laboratory facilities, equipment and personnel, in each case
suitable to the need, for carrying out the Research Program.

     2.6  Diligent Efforts.  Pfizer and Xenogen Cranbury each shall use
          ----------------
reasonably diligent efforts to achieve the objectives of the Research Program.
Xenogen Cranbury will use reasonably diligent efforts to achieve the objectives
listed in the Research Plan and Pfizer will use reasonably diligent efforts to
assist Xenogen Cranbury in such efforts.
<PAGE>

                                       8

     2.7  Key Investigators.  If *** employment with Xenogen Cranbury ends for
          -----------------
any reason and the parties are unable to agree on a successor reasonably
acceptable to Pfizer, Pfizer may terminate this Agreement pursuant to Section 8.

     2.8  Delays.  Any schedules or milestone dates of a party hereunder shall
          ------
be extended to: (i) account for any delays in obtaining information, or
materials from the other party which are not caused by any fault of such party;
and (ii) account for any modifications to the Research Plan which affect
schedules or milestone dates.  To the extent that any such delays or
modifications are projected to impose additional costs on one of the parties,
both Xenogen Cranbury and Pfizer shall mutually agree on the reimbursement due
on account of such additional costs.  Notwithstanding the foregoing, to the
extent that the non-delaying party accrues labor and other resource costs which
remain idle with respect to the Research Program due to such delays, the non-
delaying party shall be entitled to reimbursement from the other party for such
documented cost of such idled resources.

3.   PAYMENTS
     --------

     3.1  Research Program Funding.  In consideration for its performance of the
          -------------------------
Research Program, Pfizer will pay Xenogen Cranbury up to Nine Million Dollars
($9,000,000) upon receipt of invoice from Xenogen Cranbury, payable as follows:

     (a)  Within thirty (30) days of the execution of this Agreement, a fee of
          One Million Dollars ($1,000,000) to be utilized for staffing,
          administrative and equipment acquisition costs over and above normal
          on going expenses;

     (b)  Within thirty days of the execution of the Agreement, a fee of One
          Million Dollars ($1,000,000) to be utilized for Start-UP Costs;

     (c)  On the first business day of each calendar quarter during the first
          and second years of this Agreement, a payment of  *** against Xenogen
          Cranbury's invoice for such calendar quarter for work to be performed
          and costs to be incurred in such calendar quarter;

     (d)  On the first business day of each calendar quarter during the third
          year of this Agreement, a payment of *** against Xenogen Cranbury's
          invoice for such calendar quarter work to be performed and costs to be
          incurred in such calendar quarter;

     (e)  During the third year of this Agreement, payments aggregating up to
          *** in equal quarterly installments, due on the first business day of
          each quarter, against Pfizer's receipt from Xenogen Cranbury during

_________________________
*** CONFIDENTIAL TREATMENT REQUESTED
<PAGE>

                                       9

          that year of quarterly reports containing Results achieved pursuant to
          the Request Plan, including detailed data regarding the phenotypic
          analysis of Transgenic Animals and Xenogen Cranbury's invoice for such
          report; and

     (f)  Up to *** against delivery by Xenogen Cranbury to Pfizer of protocols
          for Track I and Track II Assays, as described in the Research Plan
          attached hereto, as the same may be amended by the parties, of which
          sum *** shall be payable upon Xenogen Cranbury's completion of Phase
          1B of Track I and initiating the testing of Control Animals in Track I
          Assays, the protocols for which Xenogen Cranbury shall have prepared
          and submitted to Pfizer for its approval (such approval not to be
          unreasonably withheld); and the remaining *** shall be payable upon
          Xenogen Cranbury's completion of Phase 1B of Track II and initiating
          the testing of Control Animals in Track II Assays, the protocols for
          which Xenogen Cranbury shall have prepared and submitted to Pfizer for
          its approval (such approval not to be unreasonably withheld).

     (g)  At Pfizer's option, it may be extend this Agreement for two successive
          one-year periods by providing 90 days' prior written notice to Xenogen
          Cranbury.

     (h)  If during the term of this Agreement Pfizer requests Xenogen Cranbury
          to perform phenotypic analysis on Transgenic Animals in addition to
          those Trangenic Animals identified in the Research Plan, Xenogen
          Cranbury will perform such services, allocating its capacity to
          perform such services for Pfizer on a priority basis, to the extent it
          is reasonably able to do so, consistent with Xenogen Cranbury's
          existing and anticipated contractual commitments. Such services shall
          be priced at the same rate as reflected in the Research Plan.

     3.2  Payment.  All payments by Pfizer under this Agreement shall be paid in
          -------
U.S. currency and shall be non-refundable.  Pfizer shall make such payments in
such form and to an account as specified by Xenogen Cranbury's invoices.

     3.3  Records.  Xenogen Cranbury shall keep for three (3) years from the
          -------
conclusion of each calendar year complete and accurate records of its costs and
expenses incurred hereunder.  The records shall conform to good accounting
principles as applied to a similar company similarly situated.  Pfizer shall
have the right, at its own expense, during the term of this Agreement and during
the

_________________________
*** CONFIDENTIAL TREATMENT REQUESTED

<PAGE>

                                       10

subsequent three-year period to appoint an independent certified public
accountant reasonably acceptable to Xenogen Cranbury to inspect said records to
verify the accuracy of such expenditures of efforts, pursuant to each Research
Plan. Upon reasonable notice by Pfizer, Xenogen Cranbury shall make its records
available for inspection by the independent certified public accountant during
regular business hours at the place or places where such records are customarily
kept, to verify the accuracy of the expenditures of efforts. This right of
inspection shall not be exercised more than once in any calendar year and not
more than once with respect to records covering any specific period of time. All
Xenogen Cranbury information concerning such expenditures of efforts, and all
information learned in the course of any audit or inspection, shall be Xenogen
Cranbury Confidential Information and not used or disclosed by Pfizer except to
the extent necessary for Pfizer to enforce its rights under this Agreement or to
comply with law. The failure of Pfizer to request verification of any
expenditures of efforts before or during the three-year period shall be
considered acceptance by Pfizer of the accuracy of such expenditures of efforts,
and Xenogen Cranbury shall have no obligation to maintain any records pertaining
to such report or statement beyond such three-year period. The findings of such
inspection, if any, shall be binding on the parties.

4.   TREATMENT OF CONFIDENTIAL INFORMATION
     -------------------------------------
     4.1  Confidentiality
          ---------------

          4.1.1  Except as expressly provided herein, the parties agree that,
for the term of this Agreement and for five (5) years thereafter, each party
shall protect from disclosure and shall not use for any purpose as contemplated
by this Agreement, any Confidential Information of the other party (Xenogen
Cranbury Confidential Information and Pfizer Confidential Information, as the
case may be).  Each party acknowledges that the Confidential Information of the
other party constitutes highly valuable, proprietary information which is not
publicly available.

          4.1.2  Each party shall only disclose Confidential Information of the
other party to its officers, employees or agents or those of its Affiliates to
the extent necessary for such party to perform its responsibilities under this
Agreement.  Each party shall take such actions, and shall cause its Affiliates
and sublicensees to take such action, to preserve the confidentiality of the
other party's Confidential Information as it would customarily take to preserve
the confidentiality of its own Confidential Information.  On the first to occur
of the termination or expiration of this Agreement or the other party's written
request, each party will return, within sixty (60) days, all Confidential
Information of the other party, including all copies and extracts of documents,
except for one (1) copy
<PAGE>

                                       11

which each party may keep solely to enable it to comply with its continuing
obligations under this Agreement.

          4.1.3  Each party represents and covenants that all of its employees,
and any consultants of such party participating in the Research Program with
access to Program Technology, Xenogen Cranbury Technology, Pfizer Technology,
Xenogen Cranbury Confidential Information, or Pfizer Confidential Information
are, and during the term of this Agreement shall continue to be, bound by
agreement to maintain such information in confidence and use them only for the
purposes of this Agreement.

     4.2  Use by Xenogen Cranbury of Data Relating to Level I and Level II
          ----------------------------------------------------------------
Assays Performed on Pfizer Control Animals.  At any time, Xenogen Cranbury may
------------------------------------------
disclose to Third Parties results of Level I and Level II Assays performed on
Control Animals, provided that under no circumstances shall such disclosure
contain any information relating to any Pfizer Compounds, including Results
derived from animals tested with Pfizer Compounds.

     4.3  Use By Pfizer of Data Relating to Level II Assays Performed on Control
          -------------------------------------------------------------- -------
Animals of Third Parties.  During the term of this Agreement, if Xenogen
------------------------
Cranbury uses any Level II Assays to perform Contract Research Services, it will
make available to Pfizer at no charge and in a reasonably timely manner a copy
of the report containing the results of such Level II Assays (a) as such results
pertain to control animals used in such Level II Assays, (b) to the extent that
the Third Party does not prohibit Xenogen Cranbury from providing such
information and (c) subject to Pfizer agreeing to use such information only for
internal research purposes.

     4.4  Publicity.  Except as required by law, and except for a mutually
          ---------
approved press release to be issued upon signing of this Agreement, neither
party may disclose the terms of this Agreement nor the research described in it
without the written consent of the other party, which consent shall not be
unreasonably withheld; provided, however, that Xenogen Cranbury may disclose the
terms, or provide copies of this Agreement as necessary in the normal course of
business to bankers, investors and others to obtain financing.

     4.5  Disclosure Required by Law.  If either party is required by law to
          ---------------------------
disclose any Confidential Information of the other party, in connection with a
legal or administrative proceeding, such party will promptly notify the other
party in writing of such requirement or request. If the party whose Confidential
Information is the subject of such requested disclosure seeks appropriate
protective orders or other remedies to prevent or limit such disclosure, the
other party will cooperate with such effort. If the party whose Confidential
Information is the
<PAGE>

                                       12

subject of such requested disclosure fails to obtain such remedy, or provides
the other party with a written waiver of its confidentiality obligations
regarding the Confidential Information covered by such legal requirement or
request, then the other party may comply with such requirement or request by
disclosing only such portion of Confidential Information as its legal counsel
determines it is required to disclose.

     4.6  Disclosure of Inventions.  If, in the course of performing the
          ------------------------
Research Program, any employee or consultant of either party makes any invention
within Program Technology, then such party shall promptly inform the other of
such invention.  Xenogen Cranbury shall cooperate with Pfizer, at Pfizer's
expense, to prosecute and protect any patents or other intellectual property
rights in such invention.  Such cooperation shall include without limitation
identification of all inventors and assignment by all inventors of patent or
other rights to Pfizer in such invention.

     4.7  Publication. Notwithstanding this Agreement's provisions regarding
          -----------
confidentiality, results obtained in the course of the Research Program may be
submitted for publication only after scientific review by the Research Committee
and subsequent approval by management of both Xenogen Cranbury and Pfizer, who's
approval or disapproval shall be given within thirty (30) days of their receipt
of manuscripts and within fourteen (14) days of their receipt of an abstract for
presentation at, or inclusion in the proceedings of a scientific meeting, or for
a transcript of an oral presentation to be given at a scientific meeting.

5.   INTELLECTUAL PROPERTY RIGHTS
     ----------------------------

     5.1  Ownership. Xenogen Cranbury Technology shall be owned by Xenogen
          ---------
Cranbury.  All Pfizer Technology and Program Technology made in connection with
the Research Program shall be owned by Pfizer.

     5.2  Licenses to Pfizer.
          ------------------

          5.2.1  Subject to the terms and conditions of this Agreement, Xenogen
Cranbury grants to Pfizer a perpetual, worldwide, non-exclusive, royalty-free
license to make and use, but not to sell, Xenogen Cranbury Technology (i) for
Pfizer to perform the Research Program, and (ii) to the extent necessary for
Pfizer to use the Program Technology.

          5.2.2  Subject to the terms and conditions of this Agreement, Xenogen
Cranbury grants to Pfizer a perpetual, worldwide, non-exclusive, royalty-free
license, without the right to sublicense, to make and use, but not to sell the
Level IIIXC Assays.  In addition, Pfizer may use the Level IIIXC Assays with
Third
<PAGE>

                                       13

Parties provided only that Pfizer shall own all and any intellectual property
resulting from such use.

     5.3  Licenses to Xenogen Cranbury
          ----------------------------

          5.3.1   Subject to the terms and conditions of this Agreement, Pfizer
grants to Xenogen Cranbury a worldwide, non-exclusive, royalty-free license to
make and use, but not to sell Pfizer Technology (i) for Xenogen Cranbury to
perform the Research Program, and (ii) to the extent necessary for Xenogen
Cranbury to use the Program Technology within the scope of the license granted
in 5.3.2.

          5.3.2  Subject to the terms and conditions of this Agreement, Pfizer
grants to Xenogen Cranbury a worldwide, perpetual, non-exclusive, royalty-free
license, without the right to sublicense, to make, use, and sell Program
Technology, other than Level IIIP Assays. For the avoidance of doubt, pursuant
to this Section 5.3.2 Pfizer agrees that Xenogen Cranbury may disclose to Third
Parties, any and all protocols relating to the Program Technology (other than
Level IIIP Assays) in connection with Xenogen Cranbury's performance of Contract
Research Services for Third Parties.

          5.3.3  Subject to the terms and conditions of this Agreement, Pfizer
grants to Xenogen Cranbury a perpetual worldwide, non-exclusive, royalty-free
license, without the right to sublicense, to make, use, and sell Level IIIP
Assays to perform Contract Research Services after the Period of Exclusivity.
For the avoidance of doubt, pursuant to this Section 5.3.3 Pfizer agrees that
Xenogen Cranbury may disclose to Third Parties, any and all protocols relating
to the Level IIIP Assays in connection with Xenogen Cranbury's performance of
Contract Research Services for Third Parties after the Period of Exclusivity.

6.   ACQUISITION OF RIGHTS FROM THIRD PARTIES
     ----------------------------------------

     During the Contract Period, Xenogen Cranbury and Pfizer shall each promptly
notify each other of any appropriate opportunities to acquire in any manner from
third parties, technology or patents or information which it proposes to use in
the course of performing the Research Program.  Xenogen Cranbury and Pfizer
shall discuss if such rights should be acquired in connection with the Research
Program and, if so, whether by Xenogen Cranbury, Pfizer or both and how the
costs for such acquisition should be allocated, it being understood that nothing
herein shall obligate either party to obtain such rights or, if it does acquire
such rights, to make such rights available for use in the Research Program.
<PAGE>

                                       14

7.   OTHER AGREEMENTS
     ----------------

     This Research Agreement, together with its Exhibits, sets forth the entire
agreement between the parties with respect to the subject matter and supersede
all other agreements and understandings between the parties with respect to
same.

8.   TERM, TERMINATION AND DISENGAGEMENT
     -----------------------------------

     8.1  Term.  Unless sooner terminated as provided below or extended by
          ----
mutual agreement of the parties, this Agreement shall expire on December 28,
2003.

     8.2  Events of Termination.  The following events shall constitute events
          ---------------------
of termination ("Events of Termination"):

          (a)  if any written representation or warranty by Xenogen Cranbury or
Pfizer, made in Section 9.1 shall prove to have been incorrect in any material
respect when made; and

          (b)  Xenogen Cranbury or Pfizer shall fail in any material respect to
perform or observe any term, covenant or understanding contained in this
Agreement or in any of the other documents or instruments delivered pursuant to,
or concurrently with, this Agreement, and any such failure shall remain
unremedied for thirty (30) days after written notice to the failing party.

          Except as provided in Section 8.2(b), upon the occurrence of any Event
of Termination, the party not responsible may, by written notice to the other
party, terminate this Agreement.

     8.3  Effects of Termination.
          ----------------------

          8.3.1     Termination of this Agreement by either party pursuant to
Section 8.2 will not terminate the confidentiality obligations and the
exclusivity and licenses pursuant to Section 4.1, 5.2 and 5.3.

          8.3.2     In the event of termination by either party pursuant to this
Section 8, neither party shall be liable to the other because of such
termination, for compensation, reimbursement of damages on account of the loss
of prospective profits, of anticipated sales or on account of expenditures,
inventory, investments, leases or commitments in connection with the business or
goodwill of Xenogen Cranbury or Pfizer.
<PAGE>

                                       15

          8.3.3     Notwithstanding the foregoing Section 8.3.2, termination of
this Agreement for any reason shall not release any party hereto from any
liability which, at the time of such termination, has already accrued to the
other party or which is attributable to a period prior to such termination nor
preclude either party from pursuing any rights and remedies it may have
hereunder or at law or in equity with respect to any breach of this Agreement,
including without limitation Xenogen Cranbury's right to receive all payments
accrued under Section 3.

9.   REPRESENTATIONS AND WARRANTIES; LIMITATION OF LIABILITY
     -------------------------------------------------------

     9.1  Representations, Warranties and Covenants.  Xenogen Cranbury and
          -----------------------------------------
Pfizer each represents and warrants as follows:

          9.1.1  It is a corporation duly organized, validly existing and is in
good standing under the laws of the States of Ohio and Delaware, respectively,
is qualified to do business and is in good standing as a foreign corporation in
each jurisdiction in which the conduct of its business or the ownership of its
properties requires such qualification; and it has all requisite power and
authority, corporate or otherwise, to conduct its business as now being
conducted, to own, lease and operate its properties and to execute, deliver and
perform this Agreement.

          9.1.2  The execution, delivery and performance by it of this Agreement
have been duly authorized by all necessary corporate action and do not and will
not (a) require any consent or approval of its stockholders beyond the approvals
already obtained, (b) violate any provision of any law, rule, regulations,
order, writ, judgement, injunction, decree, determination or award presently in
effect having applicability to it or any provision of its certificate of
incorporation or by-laws or (c) result in a breach of or constitute a default
under any material agreement, mortgage, lease, license, permit or other
instrument or obligation to which it is a party or by which it or its properties
may be bound or affected.

          9.1.3  This Agreement is a legal, valid and binding obligation of it
enforceable against it in accordance with its terms and conditions, except as
such enforceability may be limited by applicable bankruptcy, insolvency,
moratorium, reorganization or similar laws, from time to time in effect,
affecting creditor's rights generally.

          9.1.4  It is not under, and will not enter into, any obligation to any
person, or entity, contractual or otherwise, that is conflicting or inconsistent
in any respect with the terms of this Agreement or that would impede the
diligent and complete fulfillment of its obligations.
<PAGE>

                                       16

          9.1.5  It has the right, power and title to enter into this Agreement
and grant the rights and licenses and/or sublicenses granted herein.

     9.2  Disclaimer of Warranties.  EXCEPT FOR THE EXPRESS WARRANTY SET FORTH
          ------------------------
ABOVE IN SECTION 9.1, NEITHER XENOGEN CRANBURY NOR PFIZER MAKES ANY OTHER
WARRANTIES (EXPRESS, IMPLIED, STATUTORY OR OTHERWISE) WITH RESPECT TO THE
XENOGEN CRANBURY TECHNOLOGY, PFIZER TECHNOLOGY, AND PROGRAM TECHNOLOGY, AND
SPECIFICALLY DISCLAIMS ANY AND ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND
FITNESS FOR A PARTICULAR PURPOSE, AND ALL WARRANTIES OF NONINFRINGEMENT OF THIRD
PARTY INTELLECTUAL PROPERTY RIGHTS.

     9.3  LIMITATION OF LIABILITY.  IN NO EVENT SHALL EITHER PARTY BE LIABLE TO
          -----------------------
THE OTHER OR ANY OTHER ENTITY FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL OR
INDIRECT DAMAGES, UNLESS SUCH PARTY DEMONSTRATES THAT THE OTHER PARTY'S BREACH
CONSTITUTED WILLFUL MISCONDUCT OR GROSS NEGLIGENCE.

     9.4  Covenants.  Throughout the Contract Period, Xenogen Cranbury and
Pfizer each shall:

          9.4.1  maintain and preserve its corporate existence, rights,
franchises and privileges in the jurisdiction of its incorporation, and qualify
and remain qualified as a foreign corporation in good standing in each
jurisdiction in which such qualification is from time to time necessary or
desirable in view of their business and operations or the ownership of their
properties; and

          9.4.2  comply in all material respects with the requirements of all
applicable laws, rules, regulations and orders of any government authority to
the extent necessary to conduct the Research Program, except for those laws,
rules, regulations, and orders it may be contesting in good faith.

10.  INDEMNIFICATION
     ---------------

     Pfizer and Xenogen Cranbury each will indemnify, defend and hold each other
harmless for any and all damages, settlements, costs, legal fees and other
expenses incurred in connection with a claim by a third party against either
party based on any action or omission of the indemnifying party's agents,
employees, or officers related to its obligations under this Agreement;
provided, however, that the foregoing shall not apply (i) if the claim is found
to be based upon the gross
<PAGE>

                                       17

negligence, recklessness or willful misconduct of the party seeking
indemnification; or (ii) if such party fails to give the other party prompt
notice of any claim it receives and such failure materially prejudices the other
party with respect to any claim or action to which its obligation pursuant to
this Section applies. Notwithstanding the foregoing, Pfizer hereby expressly
agrees to indemnify, defend and hold harmless Xenogen Cranbury (and all
officers, directors, agents and Affiliates of Xenogen Cranbury) for any and all
claims arising from clinical trials pursued by Pfizer or its Affiliates and/or
sublicensees, the exercise of rights granted to Pfizer under Section 5.2 and/or
claims arising from patent rights, Pfizer patent rights, Program Technology and
Pfizer Technology except for intellectual property claims with respect to
Xenogen Cranbury patent rights, or Xenogen Cranbury Technology. The indemnifying
party agrees to pay, subject to the limitations set forth herein, any final
judgement entered against the indemnified party on such issue in any such claim
defended by the indemnifying party. Each party shall cooperate with the other
during the course of such a claim, and the indemnifying party shall keep the
indemnified party(ies) reasonably informed of the progress and status of the
claim. The indemnifying party, in its sole discretion, shall choose legal
counsel, shall control the defense of such claim or action and shall have the
right to settle same on such terms and conditions it deems advisable.

11.  NOTICES
     -------

     All notices shall be in writing mailed via certified mail, return receipt
requested, courier, or facsimile transmission addressed as follow, or to such
other address as may be designated from time to time:

     If to Pfizer:            Pfizer Global Research & Development
                              Eastern Point Road
                              Groton, CT 06340
                              Attention:  President of Strategic Operations -
                              PGRD-Groton
                              copy to: Assistant General Counsel - PGRD - Groton

     If to Xenogen Cranbury:  Xenogen Biosciences
                              5 Cedar Brook Drive
                              Cranbury, NJ 08512

         with a copy to:      Xenogen Corporation
                              860 Atlantic Avenue
<PAGE>

                                       18

                              Alameda, CA  94501
                              Attn:  General Counsel

Notices shall be deemed given as of the date received at the above specified
address.

12.  GOVERNING LAW
     -------------

     This Agreement shall be governed by and construed in accordance with the
laws of the State of New Jersey, without reference to its conflict of laws
rules.  The U.N. Convention for the Sale of Goods shall not apply. The exclusive
venue of any dispute arising out of or in connection with the performance or
breach of this Agreement shall be the New Jersey state courts located in
Middlesex County, New Jersey or the U.S. district court for the District of New
Jersey.

13.  MISCELLANEOUS
     -------------

     13.1 Binding Effect.  This Agreement shall be binding upon and inure to the
          --------------
benefit of the parties and their respective legal representatives, successors
and permitted assigns.

     13.2 Headings.  Paragraph headings are inserted for convenience of
          --------
reference only and do not form a part of this Agreement.

     13.3 Counterparts.  This Agreement may be executed simultaneously in two or
          ------------
more counterparts, each of which shall be deemed an original.  Signatures may be
transmitted via facsimile, thereby constituting the valid signature and delivery
of this Agreement.

     13.4 Amendment, Waiver.  This Agreement may be amended, modified,
          -----------------
superseded or cancelled, and any of the terms may be waived, only by a written
instrument executed by each party or, in the case of waiver, by the party or
parties waiving compliance.  The delay or failure of any party at any time or
times to require performance of any provisions shall in no manner affect the
rights at a later time to enforce the same.  No waiver by any party of any
condition or of the breach of any term contained in this Agreement, whether by
conduct, or otherwise, in any one or more instances, shall be deemed to be, or
considered as, a further or continuing waiver of any such condition or of the
breach of such term or any other term of this Agreement.

     13.5 No Third Party Beneficiaries.  No third party including any employee
          ----------------------------
of any party to this Agreement shall have or acquire any rights by reason of
this
<PAGE>

                                       19

Agreement. Nothing contained in this Agreement shall be deemed to constitute the
parties partners with each other or any third party.

     13.6 Assignment and Successors.  This Agreement may not be assigned by
          -------------------------
either party, except that each party may assign this Agreement and the rights
and interests of such party, in whole or in part, to any of its Affiliates, any
purchaser of all or substantially all of its assets related to the subject
matter of this Agreement, or to any successor corporation resulting from any
merger or consolidation of such party with or into such corporations.

     13.7 Force Majeure. Neither Pfizer nor Xenogen Cranbury shall lose any
          -------------
rights hereunder or be liable to the other for damages or losses (except for
payment obligations) on account of failure of performance by the defaulting
party if the failure is occasioned by war, strike, fire, Act of God, earthquake,
flood, lockout, embargo, governmental acts or orders or restrictions, failure of
suppliers, or any other reason where failure to perform is beyond the reasonable
control, and not caused by the negligence, intentional conduct or misconduct, of
the nonperforming party and the nonperforming party has exerted all reasonable
efforts to avoid or remedy such force majeure; provided, however, that in no
event shall a party be required to settle any labor dispute or disturbance.

     13.8 Severability.  If any provision of this Agreement is or becomes
          ------------
invalid or is ruled invalid by any court of competent jurisdiction or is deemed
unenforceable, it is the intention of the parties that the remainder of the
Agreement shall not be affected so long as the essential benefits of this
Agreement remain enforceable and obtainable.
<PAGE>

                                       20

     IN WITNESS WHEREOF, the parties have caused this Agreement to be executed
by their duly authorized representatives.

PFIZER INC                                       XENOGEN BIOSCIENCES

By:/s/ George M. Milne, Jr.       By: /s/ Pamela Reilly Contag
   ------------------------           ------------------------

Name:  George M. Milne, Jr.       Name:   Pamela Reilly Contag

Title: Senior Vice President      Title:  President
<PAGE>

                                       21

                                   EXHIBIT A

                                      ***

_________________________
*** CONFIDENTIAL TREATMENT REQUESTED
<PAGE>

                                       22

                                   EXHIBIT B

                                      ***

_________________________
*** CONFIDENTIAL TREATMENT REQUESTED
<PAGE>

                                       23

                                   EXHIBIT C

                                      ***
________________________
***CONFIDENTIAL TREATMENT REQUESTED

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00019-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00019-of-00352.parquet"}]]